Moderna Announces First Participant Dosed in Phase I Study of Its IL-2 mRNA Therapeutic

Moderna, Inc. announced the first participant has been dosed in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2 modified for the expansion of regulatory T cells.